Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive...
-
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support...
-
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
-
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced...
-
EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in...
-
Curtain Raiser for Q4 Earnings
-
MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair,...
-
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in...
-
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid® removes...
-
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 ...